Ágnes Márk

Expression of Certain Leukemia/Lymphoma Related microRNAs and its Correlation with Prognosis in Childhood Acute Lymphoblastic Leukemia

Karolina Nemes, Monika Csóka, Noémi Nagy et al. · Pathology & Oncology Research · 2014 · 56 citations

Hematological Malignancy, Tumor Biology, Medicine +9

Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease – a combined tissue microarray, in vitro and in vivo study

Ágnes Márk, Melinda Hajdú, Zsófia Váradi et al. · BMC Cancer · 2013 · 39 citations · Full text

Expression of mTORC1/2-related proteins in primary and brain metastatic lung adenocarcinoma

Ildikó Krencz, Anna Sebestyén, Katalin Fábián et al. · Human Pathology · 2016 · 31 citations

Medicine, Pathology, Mtorc1/2-related Proteins +5

The Activated Targets of mTOR Signaling Pathway Are Characteristic for PDGFRA Mutant and Wild-type Rather Than KIT Mutant GISTs

Zoltàn Sápi, Tibor Füle, Melinda Hajdu et al. · Diagnostic Molecular Pathology · 2011 · 30 citations

Engineering, Pathology, Pdgfra Mutant +23

Mammalian Target of Rapamycin (mTOR) Activity Dependent Phospho-Protein Expression in Childhood Acute Lymphoblastic Leukemia (ALL)

Karolina Nemes, Anna Sebestyén, Ágnes Márk et al. · PLoS ONE · 2013 · 27 citations · Full text

Mixed-phenotype Acute Leukemia, Immunology, Increased Mtor Activity +16